Childhood Obesity Treatment Gap

Childhood obesity continues to rise at an alarming rate in the United States, mirroring trends seen in adults but with even more concerning long-term implications. Today, more than 150 million Americans are living with obesity, including roughly 15 million children. While most people recognize that obesity is linked to serious conditions such as Type 2 diabetes, heart disease, and sleep apnea, fewer realize that these illnesses are increasingly affecting younger populations.

One of the most troubling aspects of obesity is that its impact compounds over time. The longer the body carries excess weight, the greater the cumulative stress placed on organs, metabolism, and overall health. When obesity begins in childhood, that timeline of exposure becomes significantly longer — often leading to more severe complications in adulthood.

Evan P. Nadler, M.D., the founder of ProCare Consultants and ProCare TeleHealth, penned an article for Clinical Leader, providing his take on why excluding children from clinical trials might present obstacles in the proper treatment of childhood obesity with weight loss drugs.

He wrote:

With most diseases, the longer you have it, the worse it gets. Obesity is no different. The damage is cumulative. It’s not just about how much you weigh — it’s about how long your body has been exposed to that weight. So one would think that the imperative to find solutions for childhood obesity would be front and center for those who are involved in clinical research involving the next generation of anti-obesity medicines. Unfortunately, that isn’t the case.

Despite this urgency, children remain largely underrepresented in the rapidly advancing field of anti-obesity drug development.

The landscape of obesity treatment has changed dramatically in recent years. Breakthrough medications have transformed how clinicians approach weight management, offering new hope for patients who previously had limited options.

Recent approvals from the U.S. Food and Drug Administration have brought injectable treatments such as semaglutide and tirzepatide into mainstream medical practice, with studies showing substantial weight loss outcomes. Researchers are also developing oral versions of these medications, along with next-generation therapies like orforglipron, maritide, and retatrutide.

Some of these emerging treatments target multiple metabolic pathways at once. In clinical trials, triple-receptor therapies have demonstrated weight-loss results comparable to bariatric surgery — an outcome that was nearly unimaginable just a decade ago.

However, most of these advancements are focused on adult populations. Currently, only a limited number of GLP-1–based medications are approved for adolescents ages 12 and older. Even then, options remain restricted, and some require daily injections, which can be difficult for younger patients to maintain. Meanwhile, several promising drugs remain years away from pediatric approval.

Why children are often left out of clinical trials

A major reason for the treatment gap lies in how clinical trials are structured. Pharmaceutical companies typically complete adult trials first before expanding research into pediatric populations. While safety considerations play a role, regulatory frameworks also contribute to delays.

In the United States, pediatric studies are encouraged but not always required early in the drug development process. Companies may postpone these trials until adult approvals are secured, which often results in multi-year delays before children gain access to new therapies.

This delay can create arbitrary access gaps. For example, a medication approved for an 18-year-old may not be available for a 17-year-old — even though the medical condition is essentially identical.

Because adult markets are larger and more profitable, pediatric studies are often deprioritized. Unfortunately, this approach overlooks the long-term health benefits of early intervention.

How Europe takes a different approach

Regulatory policies differ internationally. Within the European Union, pharmaceutical companies must submit a Pediatric Investigation Plan before completing adult trials for new medications. While the pediatric studies themselves may still occur later, the requirement ensures that children are part of the development strategy from the beginning. This structured planning process has resulted in more consistent pediatric drug research compared to the U.S., where early inclusion is often optional.

Despite groundbreaking progress in obesity pharmacotherapy, many of the newest medications still lack clear pediatric development timelines. Public regulatory databases show limited planning for children in several ongoing drug pipelines, reinforcing concerns that young patients may wait years before benefiting from new therapies.

The contrast is striking. Innovation is accelerating, yet access remains uneven.

The growing childhood obesity crisis highlights the need for a shift in how treatments are developed and approved. Early intervention — whether through lifestyle programs, behavioral care, or medical therapy — can dramatically change long-term health outcomes.

As new anti-obesity medications continue to reshape treatment possibilities, experts increasingly call for regulatory reforms that prioritize pediatric inclusion from the start. Without that change, millions of children may remain on the sidelines of one of the most significant medical advancements in metabolic health.

Dr. Nadler wrote:

So what does this all mean for children with obesity in the U.S.? Despite all the GLP-1- development, children are not part of the gameplan… The time has come for the FDA to rethink how it approaches clinical trials in children for the sake of the 15 million children with obesity…

Your responses and feedback are welcome!

Source: “The Problem With Excluding Children From GLP-1 Trials In The U.S.,” Clinical Leader, 2/19/26
Source: “Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction,” FDA, January 2025
Image by Anna Shvets/Pexels

The New U.S. Dietary Guidelines Spark Praise, Pushback, and Policy Shifts

Since their release in early January, the new U.S. Dietary Guidelines for Americans have stirred intense debate across the food industry, healthcare community, and public policy landscape. Touted by some as a long-overdue course correction and criticized by others as inconsistent or politically influenced, the updated guidance marks a notable shift in tone, particularly around refined carbohydrates and ultra-processed foods.

But while parts of the recommendations are being welcomed as progress, other sections are drawing skepticism over scientific rigor, industry influence, and practical implementation, especially in schools.

Here’s a closer look at what’s changed, who stands to benefit, and what it could mean for Americans.

A shift away from refined carbohydrates

One of the most talked-about updates involves a stronger acknowledgment of the risks associated with refined carbohydrates and ultra-processed foods.

Tim Spector, M.D., a professor of genetic epidemiology at King’s College and scientific co-founder of ZOE, a personalized nutrition program, said in an interview with The Food Institute:

For the first time in a long while, we’re seeing official guidance acknowledge something that researchers and clinicians have been observing for years: Many chronic diseases improve when refined carbohydrate intake is reduced.

For many clinicians, this represents a meaningful departure from decades of nutrition advice that emphasized low-fat diets while often overlooking the role of highly processed carbohydrates in metabolic disease.

However, Dr. Spector cautioned that the guidance may lack practical clarity. He said,

The documents don’t go into much detail on how to do this well, and that’s an important caveat. But even so, this represents a genuinely welcome shift away from nutritional advice that has dominated for the last two decades and has proven remarkably resistant to change despite mounting evidence that it hasn’t delivered better health outcomes.

In other words, while the direction may be promising, the roadmap remains incomplete.

A “mixed bag” of recommendations

Not all experts are fully on board. Evan Nadler, M.D., a childhood obesity treatment expert who previously ran the Childhood Obesity Programs at Children’s National Hospital in Washington, D.C., described the new guidelines as a “mixed bag.” He said:

The advice to limit ultra-processed food, sugar, and refined carbohydrate intake is long overdue and likely helpful for almost everybody, but the advice to increase red meat and whole milk intake isn’t evidence-based and could be especially harmful for those at risk for cardiovascular disease.

He also questioned recommendations around protein intake:

Similarly, Americans already eat plenty of protein so there is no basis to increase protein intake as advocated in the recommendations. Increased protein intake can be an issue for those with kidney disease in particular.

These concerns reflect an ongoing tension in nutrition science: balancing population-wide guidance with individual health risks.

What about gut health?

The guidelines’ recognition of gut health has also drawn mixed reactions. Fiber, prebiotics, and diverse plant-based foods are widely associated with improved gut microbiome health. Critics argue that if gut health is to be a priority, plant-forward foods should take center stage in national guidance.

Kaitlin Voicechovski, lead registered dietitian at Oshi Health, welcomes the shift but believes the emphasis could go further. She said:

If this were truly a gut-friendly food pyramid, a few things might be higher up: fiber-rich foods, whole grains, and plant-based protein sources like beans.

Which industries stand to benefit?

Beyond nutritional science, some experts are questioning the influence of powerful food industry stakeholders. Here’s Dr. Nadler’s take:

Clearly, the dairy and beef industries are the big winners here, and also U.S. [farmers] in general could stand to benefit. While RFK claims to have ‘radical transparency’ when it comes to the pharmaceutical industry, the impact of the National Dairy Council and the National Cattlemen’s Beef Association on the new dietary guidelines has been swept under the rug a bit.

Concerns about industry ties are not new in the development of federal dietary guidelines. Critics argue that transparency around financial relationships remains insufficient.

Dotsie Bausch, an Olympic silver medalist and founder of the vegan nonprofit Switch4Good, was more direct in her critique, stating that six of the nine experts on the dietary guidelines’ panel are “taking money from big meat and dairy.”

She also questioned messaging around “real food”:

They constantly repeat for Americans to eat ‘real food,’ but when in history have any of the guidelines suggested for us to eat fake food? People are well aware their trips to McDonalds and Taco Bell are not healthy choices.

This debate underscores a broader philosophical divide: Should national guidelines lean more heavily toward plant-based patterns, or maintain a more omnivorous framework?

Impact on schools

One area where many agree progress has been made is in reducing children’s exposure to sugar and artificial sweeteners. Dr. Spector described this aspect of the guidance as a “public health win,” noting that limiting added sugars in school meals could help address rising rates of childhood obesity and metabolic disorders.

However, translating guidelines into practice is easier said than done. Lori Nelson of the Chef Ann Foundation, a nonprofit that promotes scratch cooking in schools, compared assembling a school meal to a puzzle. She told NPR:

When you think about the guidelines, there’s so many different pieces that you have to meet. You have to meet calorie minimums and maximums for the day and for the week. You have to meet vegetable subgroup categories.

Infrastructure presents another barrier. Many school cafeterias were built decades ago and designed primarily for reheating pre-prepared food rather than cooking meals from scratch. Budget constraints further complicate efforts to incorporate more whole, minimally processed ingredients.

A new era for plant-based options in schools?

In a related development, the recently signed Freedom in School Cafeterias and Lunches (FISCAL) Act now requires schools to provide plant-based milk options to students whose parents request them. This would be the first time in the nearly 80-year history of the national school lunch program.

This move could signal broader flexibility in how schools interpret and implement federal nutrition policy, particularly as plant-based eating continues to gain popularity among families.

It would also be interesting to follow the news and see how the new food pyramid would compare to the WHO’s recently issued global guidelines for healthier school meals.

Your responses and feedback are welcome!

Source: “The New Food Pyramid: Pros, Cons, Potential Conflicts of Interest,” The Food Institute, 2/11/26
Source: “How the new dietary guidelines could impact school meals,” NPR, 2/5/26
Image by Anastasia  Shuraeva/Pexels

WHO: Global Nutrition Progress Is Stalling

A recent report presented to the World Health Organization (WHO) Executive Board delivered troubling news: global progress on maternal, infant, and child nutrition has largely stalled. In some areas, it’s even moving backward.

Despite years of international commitments and development programs, six major global nutrition targets are now officially “off track.” Rising anemia rates among women, persistent childhood stunting (being too short for their age due to chronic undernutrition), increasing childhood overweight, and stagnant improvements in birth outcomes reveal a growing crisis that experts are calling a silent epidemic, particularly across Africa and other vulnerable regions.

The implications are profound. Nutrition is not just about food — it shapes survival, lifelong health, cognitive development, economic productivity, and equity.

Let’s take a closer look at what’s happening and why it matters.

Anemia in women is a reversing trend

One of the clearest signs of regression is the rising prevalence of anemia in women of reproductive age. Global commitments under Sustainable Development Goal 2 (Zero Hunger) aim to cut anemia rates in half by 2030. Instead of declining, rates have increased from 27.6% in 2012 to 30.7% in 2023.

Anemia — often caused by iron deficiency but also linked to infections, poor diets, and poverty — reduces the body’s ability to carry oxygen in the blood. For women, this can mean increased risk of maternal mortality, higher likelihood of preterm birth, low birth weight infants, and reduced physical capacity and productivity. The rise reflects deeper systemic challenges, such as food insecurity, climate shocks, infectious diseases, gender inequality, and fragile health systems.

The double burden of malnutrition

The world is now grappling with what experts call the “double burden” of malnutrition — undernutrition and overweight existing side by side. Undernutrition remains widespread, as 150.2 million children under five are stunted.

An additional 136.3 million children could face stunting by 2030 if trends continue. Childhood wasting (dangerously low weight for height) affects 6.6% of children, well above WHO’s 5% target threshold. Low birth weight rates have barely improved, decreasing only slightly to 14.7% globally. Stunting affects brain development, school performance, and earning potential later in life. It locks families and nations into cycles of poverty.

Childhood overweight is rising

At the same time, childhood overweight has climbed to 5.5% globally. This rise is linked to food systems that increasingly provide cheap, ultra-processed foods while healthy options remain inaccessible or unaffordable. This nutritional paradox — hunger and obesity existing simultaneously — reflects structural weaknesses in global food systems.

A crisis of inequality

During WHO discussions, member states emphasized that this is not just a nutrition problem — it’s a crisis of inequality. The African region bears the highest global burden of stunting and anemia. Conflict, displacement, and climate change are worsening food insecurity.

In fragile states, entire health and supply systems are disrupted. Climate shocks destroy crops, armed conflicts displace families, and economic instability limits access to nutritious foods. The result is a compounding nutrition crisis, particularly in low-income and conflict-affected regions.

The formula marketing controversy

A heated debate also emerged over the marketing of breast milk substitutes. Several nations criticized aggressive commercial practices that promote formula feeding in vulnerable communities. Critics argue that misleading marketing undermines breastfeeding, targets low-income families, and prioritizes profits over public health.

Concerns were raised about online and cross-border marketing practices, including unregulated digital advertising and product safety recalls. Public health advocates insist that governments must strengthen monitoring and enforce international marketing codes to protect breastfeeding, which remains one of the most effective and cost-efficient interventions for infant survival.

Micronutrient supplementation

While advocacy groups pushed for stronger regulation of formula marketing, industry representatives emphasized the importance of micronutrient supplementation. Iron, folate, iodine, and calcium supplementation during pregnancy can significantly reduce anemia, maternal mortality, and preterm birth. Many experts agree that supplementation programs can be a cost-effective public health strategy, particularly in high-risk populations.

Shrinking aid in a growing crisis

Perhaps the most alarming backdrop to this discussion is declining international nutrition funding. Development assistance for nutrition is estimated to have dropped between 9% and 17% in 2025.

At the same time, no country is currently on track to meet all nutrition targets, dietary diversity is worsening in multiple regions, and vulnerable populations are expanding due to climate change and conflict. Reduced funding threatens to undo years of progress and increase preventable child deaths. Experts are calling for nutrition to be treated as an essential component of primary health care, not a secondary development issue.

The road ahead

The WHO report should be a wake-up call. Without stronger political commitment, better coordination, and sustained investment, global nutrition goals will remain out of reach.

Malnutrition may be described as a “silent epidemic,” but its consequences are anything but silent. They shape the health, survival, and potential of millions of women and children.

According to the experts, reversing the current trend will require protecting nutrition funding, strengthening primary healthcare, supporting fragile and conflict-affected regions, regulating harmful marketing practices, and building resilient and equitable food systems.

In a nutshell, nutrition is not optional — it’s foundational. And the time to act is now.

Your responses and feedback are welcome!

Source: “Maternal and Child Nutrition Backslides: WHO Report Reveals,” Health Policy Watch, 2/6/26
Source: “Maternal, infant and young child nutrition,” WHO, 12/9/25
Image by Mikhail Nilov/Pexels